8 completed, 3 withdrawn. 11 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 11 | Completed 8, Withdrawn 3 |
Follow Keratoconjunctivitis Sicca: new trials by email Literature Review of Keratoconjunctivitis Sicca trials Research Report on Keratoconjunctivitis Sicca
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya Nasal Guide - Dry Eye, Keratoconjunctivitis Sicca | Phase 4 | Completed | Oyster Point Pharma, Inc. | 30 | 2023-06-14 | 2025-05-06 |
| Effect of Cequa™ in Subjects With Dry Eye Disease CequaTM (Cyclosporine 0.09%) ophthalmic solution - Dry Eye Disease | Phase 4 | Completed | Sun Pharmaceutical Industries Limited | 135 | 2020-06-29 | 2024-02-06 |
| Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease Lifitegrast - Ocular Discomfort, Ocular Inflammation | Phase 4 | Withdrawn | University of Alabama at Birmingham | 2019-01-01 | 2019-05-17 | |
| Repository Corticotropin Injection in Keratoconjunctivitis Sicca repository corticotropin injection - Keratoconjunctivitis Sicca | Phase 4 | Withdrawn | University of Alabama at Birmingham | 2018-11-01 | 2018-12-14 | |
| Lifitegrast 5% Ophthalmic Solution and Contact Lens Dryness Lifitegrast - Contact Lens, Contact Lens Discomfort | Phase 4 | Completed | EV Clinical Trials | 21 | 2016-12-16 | 2018-09-28 |
| A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye carboxymethylcellulose 0.5%/glycerin 0.9%, sodium hyaluronate 0.18% - Dry Eye Syndromes, Keratoconjunctivitis Sicca | Phase 4 | Completed | Allergan | 80 | 2014-05-14 | 2019-04-18 |
| A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome Retaine™ - Keratoconjunctivitis Sicca | Phase 4 | Completed | Ocusoft, Inc. | 42 | 2014-05-01 | 2014-06-11 |
| Effects of Dry Eye Treatments on the Ocular Surface Dexamethasone, Artificial tear - Keratoconjunctivitis Sicca, Dry Eye Syndrome | Phase 4 | Completed | Baylor College of Medicine | 20 | 2013-02-01 | 2020-02-05 |
| Hyaluronic Acid Gels for Lower Lid Retraction Hyaluronic acid, Saline - Ectropion | Phase 4 | Withdrawn | University of California, Los Angeles | 2013-02-01 | 2014-12-03 | |
| Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD), sodium hyaluronate 0.18% (VISMED® Multi) - Dry Eye Syndromes, Keratoconjunctivitis Sicca | Phase 4 | Completed | Allergan | 82 | 2009-11-01 | 2011-09-21 |
| Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis Lotemax, Restasis - Dry Eye Disease, Keratoconjunctivitis Sicca | Phase 4 | Completed | Ophthalmic Consultants of Long Island | 5 | 2006-11-01 | 2011-07-21 |
Dry Eye Syndromes (10) · Ectropion (1) · Xerophthalmia (1)
Conjunctival Diseases (11) · Conjunctivitis (11) · Corneal Diseases (11) · Eye Diseases (11) · Keratitis (11) · Keratoconjunctivitis (11) · Lacrimal Apparatus Diseases (11) · Dry Eye Syndromes (1) · Eyelid Diseases (1)
Carboxymethylcellulose Sodium (2) · Hyaluronic Acid (2) · lifitegrast (2) · Adrenal Cortex Hormones (1) · Cyclosporine (1) · Cyclosporins (1) · Dexamethasone (1) · Glycerol (1) · Loteprednol Etabonate (1) · Lubricant Eye Drops (1) · Ophthalmic Solutions (1) · Restylane (1) · Sodium Chloride (1)
Allergan (2) · University of Alabama at Birmingham (2) · Baylor College of Medicine (1) · EV Clinical Trials (1) · Ocusoft, Inc. (1) · Ophthalmic Consultants of Long Island (1) · Oyster Point Pharma, Inc. (1) · Sun Pharmaceutical Industries Limited (1) · University of California, Los Angeles (1)
United States (8) · France (2) · United Kingdom (1)
Daniel B Rootman, MD, MSc (1) · Jason J Nichols, OD, MPH, PhD (1) · Kelly K Nichols, OD MPH PhD (1) · Maria Howard (1) · Marian Macsai, MD (1) · Stephen Pflugfelder, MD (1)